Drugs produce their effects by interacting with biological targets — proteins, lipids, or nucleic acids whose function is altered by the drug’s presence. Understanding which targets a drug engages, and how, is what distinguishes rational prescribing from empirical guesswork. This text introduces the major categories of drug targets and the mechanisms through which drugs modify their function.
Receptors
Most drugs act on receptors — proteins that normally respond to endogenous signaling molecules (neurotransmitters, hormones, cytokines). The drug binds to the receptor and either mimics or blocks the endogenous signal.
Agonists bind to the receptor and activate it. The drug produces the same type of response as the endogenous ligand, though potentially at different intensity or duration. Examples:
- Albuterol — beta-2 adrenergic agonist; activates the same receptors that epinephrine activates on bronchial smooth muscle, producing bronchodilation. Used in acute asthma and reactive airway disease, including in airway management.
- Morphine — mu-opioid receptor agonist; activates endogenous opioid receptors to produce analgesia, sedation, euphoria, and respiratory depression.
Antagonists bind to the receptor without activating it, blocking the endogenous ligand from binding. The drug prevents the normal signal from being received. Examples:
- Naloxone — mu-opioid receptor antagonist; displaces opioids from the receptor, reversing analgesia, sedation, euphoria, and respiratory depression. The pharmacological basis of opioid overdose reversal.
- Propranolol — beta-adrenergic antagonist (beta-blocker); blocks the effects of epinephrine and norepinephrine on heart rate and contractility.
Partial agonists bind to the receptor and produce a submaximal response — less activation than a full agonist, but more than an antagonist. At low receptor occupancy, they act like agonists; at high occupancy, they act like antagonists (because they prevent full agonists from binding). Examples:
- Buprenorphine — partial mu-opioid agonist; produces enough opioid effect to prevent withdrawal and reduce craving, but has a ceiling effect on respiratory depression that makes it safer than full agonists in overdose.
Enzymes
Some drugs act by inhibiting enzymes — proteins that catalyze biochemical reactions. By blocking an enzyme, the drug prevents the reaction from occurring, causing substrate accumulation or product depletion. Examples:
- NSAIDs (ibuprofen, naproxen) — inhibit cyclooxygenase (COX) enzymes, which convert arachidonic acid into prostaglandins. Prostaglandins sensitize nociceptors and mediate inflammation. Blocking their production reduces both pain and inflammation.
- ACE inhibitors (lisinopril, enalapril) — inhibit angiotensin-converting enzyme, preventing the formation of angiotensin II (a potent vasoconstrictor). The result is vasodilation and reduced blood pressure.
- SSRIs (fluoxetine, sertraline) — inhibit the serotonin reuptake transporter, increasing serotonin availability in the synaptic cleft. Technically enzyme/transporter inhibitors rather than receptor agonists.
Ion channels
Some drugs act directly on ion channels — membrane proteins that allow ions (sodium, potassium, calcium, chloride) to flow across cell membranes, generating or inhibiting electrical signals. Examples:
- Local anesthetics (lidocaine) — block voltage-gated sodium channels in peripheral nerves, preventing action potential propagation and therefore preventing pain signals from reaching the spinal cord. This is a direct pharmacological interruption of nociceptive transmission.
- Benzodiazepines (midazolam, diazepam) — enhance the effect of GABA at the GABA-A receptor (a chloride ion channel), increasing inhibitory neurotransmission. This produces sedation, anxiolysis, muscle relaxation, and anticonvulsant effects.
- Gabapentinoids (gabapentin, pregabalin) — bind to the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. Used in neuropathic pain and central sensitization states.
Selectivity is relative
No drug hits a single target. Every drug interacts with multiple receptors, enzymes, or ion channels at varying affinities. The intended therapeutic effect comes from the target with the highest affinity; side effects come from lower-affinity interactions that become significant at higher doses. The therapeutic index quantifies how much room exists between the dose that engages the high-affinity target (producing benefit) and the dose that engages lower-affinity targets (producing harm).
This is why understanding how drugs work — not just what they are prescribed for — matters for clinical reasoning. Knowing that a drug is a muscarinic antagonist explains why it causes dry mouth, urinary retention, and constipation alongside its intended effect. Knowing that two drugs both enhance serotonergic transmission explains why combining them risks serotonin syndrome. Knowing mechanism allows prediction; knowing only indication allows only protocol-following.
The TCM contrast
In traditional Chinese medicine, herbal prescriptions are formulated not by isolating single molecular targets but by composing formulas that address the patient’s overall pattern of disharmony. A formula might contain a principal herb (targeting the primary pattern), a deputy herb (supporting the principal or addressing a secondary pattern), an assistant herb (moderating harsh effects of the principal), and an envoy herb (directing the formula to a specific body region). This systems-based approach to pharmacology — treating the formula as a functional unit rather than a collection of individual drug effects — represents a fundamentally different paradigm from Western molecular pharmacology. Whether one paradigm is “better” depends on what clinical question is being asked.